Navigation Links
Indevus Pharmaceuticals To Present at RBC Capital Markets Conference
Date:12/5/2007

mpany's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(R), SANCTURA(R) XR, NEBIDO(R) , VANTAS(R) and SUPPRELIN(R) LA; the early state of products under development; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR(TM); risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; need for additional funds and corporate partners, including for the development of our products; failure to acquire and develop additional product candidates; changes in reimbursement policies and/or rates for SANCTURA, VANTAS, SUPPRELIN LA, DELATESTRYL(R) and any future products; history of operating losses and expectation of future losses; product liability and insurance uncertainties; risks relating to the Redux- related litigation; the risk that the businesses of Indevus and Valera Pharmaceuticals, Inc. will not be integrated successfully during the period following the related merger; the risk that the cost savings and any other synergies from the merger may not be fully realized or may take longer to realize than expected; market acceptance for the merger and approved products; risks of regulatory review and clinical trials; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, valuation of our Common Stock; risks related
'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
2. FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... August 01, 2014 The 2013 ... increasing 0.89 points from 75.07 in 2012. The ... tourism-related sectors and integrates them into an overall ... become increasingly more satisfied with Hong Kong over ... consistently excelling in service performance in Hong Kong ...
(Date:7/31/2014)... 31, 2014 United Theological Seminary will ... on Monday, September 15, with its 2014 Opening Convocation, ... 3440 Shroyer Rd., Kettering, OH. Dr. Emma J. Justes, ... Emma Toussant Chair will speak on “Unexpected Undercurrents: Responding ... teaching and research interests include pastoral care and counseling, ...
(Date:7/31/2014)... 31, 2014 Dr. Stewart Shofner ... the first surgeons in the United States to successfully treat ... the smallest medical device ever approved by the FDA. ... recognize the benefits of using a procedure known as Selective ... Shofner and his colleagues now recognize that this procedure is ...
(Date:7/31/2014)... Las Vegas, NV (PRWEB) July 31, 2014 ... marketing expert Adam Short that is designed to provide a ... has caught the attention of Shane Michaels, prompting an investigative ... here . , “What really speaks volumes about the success ... the tactics and strategies included in it have stayed effective ...
(Date:7/31/2014)... Cosmetic Town has introduced a secure verification ... will be able to verify their patients before the ... guarantees their authenticity. This will help prospective patients ... information that has been verified to come from a ... Town to filter out fake patients who leave fraudulent ...
Breaking Medicine News(10 mins):Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:United Theological Seminary to Open 144th Year 2Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 2Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 3Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 4Health News:Niche Profit Classroom: Review Exposes Adam Short’s Guide to Building Niche Websites 2Health News:Cosmetic Town Improves Patient Experience Through Secure Verification of Patients and Doctors 2
... RICHMOND, Va., April 29 The principal U.S. investigator,for ... for,malpractice in his use of the device by a ... No. 07-206, Circuit Court, City of Richmond, Va., ... H.,Mathews, M.D., and Midatlantic Spine Specialists, P.C. Dr. Mathews ...
... 1950 had agreement on standard outcomes, review finds , , ... the appropriate measurements for assessing drug clinical trials that ... 9,000 pediatric clinical trials conducted since 1950. , They ... none have involved children in the process to select ...
... PITTSBURGH, April 29 Mylan Inc. (NYSE: MYL ... approval,from the U.S. Food and Drug Administration (FDA) for ... mg, 2 mg and 4 mg., Trandolapril Tablets ... and generic versions of this product had total U.S.,sales ...
... A New LTCI Presentation System Designed for Today,s ... LLC, the leader in,providing long-term care insurance sales, ... announced the release of,simplifyingLTC, a LTCI presentation system ... presentation system communicates the risk of long-term care ...
... More than 50,000 doctors,have given 20 million free ... to Reach Out and Read. Partnering with doctors ... to their parents at check-ups, Reach,Out and Read ... toddlers,and preschoolers. The children,s literacy program recently reached ...
... Growth of 27-29 Percent over ... 2007 First-Quarter Year-Over-Year Highlights (adjusted for January 2008 ... two-for-one stock split): - GAAP ... from $0.52, excluding $0.05 in amortization of intangible assets ...
Cached Medicine News:Health News:Virginia Judge Rules Medical Device Pioneer Committed Malpractice 2Health News:Measurements Poor for Assessing Clinical Trials With Children 2Health News:SellingLTC.com Develops simplifyingLTC 2Health News:20 Million Kids' Books Distributed, 25% of U.S. Children in Poverty Getting Books, 50,000 Doctors Trained: Three Key Milestones for Reach Out and Read 2Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 2Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 3Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 4Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 5Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 6Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 7Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 8Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 9Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 10Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 11Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 12Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 13Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 14Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 15Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 16Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 17Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 18Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 19Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 20Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 21Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 22Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 23Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 24Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 25
(Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 Xencor ... biopharmaceutical company developing engineered monoclonal antibodies for the ... and cancer, today reported financial results for the ... review of recent business highlights. "In ... the American Thoracic Society 2014 International Conference (ATS) ...
(Date:7/31/2014)... Calif. , July 31, 2014  Cepheid (NASDAQ: ... speaking at the following conferences, and invited investors to participate ... Access Conference, New York, NY Wednesday, ... Baird Health Care Conference, New York, NY ... Time , Accessing Live Webcasts To access the ...
(Date:7/31/2014)... MOUNTAIN VIEW, Calif. , July 31, 2014 ... ) today provided an update on its pipeline ... of 2014, Alexza expects to initiate a Phase ... which is being developed for the management of ... identified two new Staccato -based product candidates ...
Breaking Medicine Technology:Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8Cepheid to Webcast Upcoming Financial Presentations 2Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6
Used for dilation of a tract to the kidney for removal of stones. Supplied sterile in peel-open packages. Intended for one-time use....
... musculofascial tract, renal capsule, and parenchyma during ... the catheter shaft. Radiopaque markers are placed ... the balloon. The radiopaque dilator/sheath assembly is ... coaxial placement of the sheath. Supplied sterile ...
... Therapy for Urinary Control offers a ... and the symptoms of overactive bladder, ... symptoms of urgency-frequency alone or in ... or could not tolerate more conservative ...
... Receiving timely, high-quality and accurate,ECG ... care. The,Quinton Eclipse Premier allows ... test results,and make a diagnosis ... sharing capabilities.,Workload is further streamlined ...
Medicine Products: